Effects of Termination or Trial Completion Clause Samples

Effects of Termination or Trial Completion. ‌ (a) Upon an early termination under Section 15.2 or 15.3 or upon Trial completion: (i) this Agreement will terminate;‌
View SourceView Similar (4)
Effects of Termination or Trial Completion. Upon an early termination under Section 15.2: (a) Investigator will immediately stop enrolling subjects into the Trial and cease administering Trial Drug to Trial Subjects and conducting Trial procedures on Trial Subjects, to the extent medically advisable; (b) Sponsor will pay a fee accrued by Institution in the performance of the Trial as of the date of notice of termination, in accordance with Attachment A, including non- cancelable obligations incurred prior to the date of notice of termination; ((c) Institution will (i) furnish to Sponsor, within thirty (30) days of the effective date of termination, all Trial Data, including completed or partially completed CRFs; and (ii) in accordance with Sponsor’s 15.3 Účinky výpovědi a dokončení k linického hodnocení. V případě předčasného ukončení (vypovězení) na základě článku 15.2: (a) zkoušející okamžitě přestane do klinického hodnocení nabírat nové subjekty hodnocení, přestane podávat studijní léčivo subjektům hodnocení a přestane provádět vyšetření subjektů hodnocení pro účely klinického hodnocení, pokud je to z lékařského hlediska možné; (b) zadavatel uhradí poskytovateli zdravotních služeb odměnu za provádění klinického hodnocení, na kterou mu vznikne nárok v souvislosti s prováděním klinického hodnocení do data jeho předčasného ukončení, v souladu s p řílohou A, včetně neodvratných nákladů, které vznikly před datem výpovědi; a (c) poskytovatel zdravotních služeb se zavazuje (i) (a) through 15.3
View SourceView Similar (2)
Effects of Termination or Trial Completion. (a) Upon an early termination under Section 13.2 or 13.3 or upon Trial completion: (i) this Agreement will terminate; (ii) Institution will cease conducting the Trial and will ensure Investigator immediately stops enrolling subjects into the Trial and ceases administering Trial Drug to Trial Subjects and conducting Trial procedures on Trial Subjects, to the extent consistent with the safety Zadavatel nebo Poskytovatel („Strana, která neporušila Smlouvu“) může tuto Smlouvu ukončit z důvodu závažného porušení některého z ustanovení této Smlouvy druhou smluvní stranou („Stranou, která porušila Smlouvu“) neprodleně po písemné výpovědi druhé smluvní straně účinné dnem následujícm po doručení, pokud k nápravě tohoto porušení nedojde do třiceti (30) dnů poté, co Strana, která porušila Smlouvu, obdrží písemné upozornění na toto porušení od Strany, která neporušila Smlouvu.
View Source
Effects of Termination or Trial Completion. ‌ (a) Upon an early termination under Section 15.2 or 15.3 or upon Trial completion: (i) this Agreement will terminate; (ii) Investigator will immediately stop enrolling subjects into the Trial and cease administering Trial Drug to Trial Subjects and conducting Trial procedures on Trial Subjects, to the extent consistent with the safety and welfare of the affected Trial Subjects; (iii) Sponsor will pay all reasonable costs accrued by Institution in the performance of the Trial as of the date of notice of termination, in accordance with Exhibit A, including non-cancelable obligations incurred prior to the date of notice of termination; (iv) any funds not due under the calculation under Section 15.4 (a)(iii), but already paid by Sponsor to Institution will be promptly returned to Sponsor; (v) Institution will (1) furnish to Sponsor, within thirty (30) days of the effective date of termination, all Trial Data, including completed or partially completed CRFs; and (2) in accordance with Sponsor’s instructions, deliver to Sponsor or, at Sponsor’s option, dispose of, all Trial Supplies and Confidential Information furnished by Sponsor or its designees to Institution or Investigator; and‌ (vi) Investigator will promptly submit final written reports to Sponsor as specified in the Protocol.
View Source
Effects of Termination or Trial Completion. Upon an early termination under Section 15.2: (a) this Agreement will terminate; (b) Investigator will immediately stop enrolling subjects into the Trial and cease administering Trial Drug to Trial Subjects and conducting Trial procedures on Trial Subjects, to the extent medically advisable; (c) Sponsor will pay all reasonable costs accrued by Institution in the performance of the Trial as of the date of notice of termination, in accordance with Attachment A, including non-cancelable obligations incurred prior to the date of notice of termination; (d) any funds not due under the foregoing calculation but already paid by Sponsor to Institution will be promptly returned to Sponsor; and (e) Institution will (i) furnish to Sponsor, within thirty (30) days of the effective date of termination, all Trial Data, including completed or partially completed CRFs; and (ii) in accordance with Sponsor’s instructions, deliver to Sponsor or, at Sponsor’s option, dispose of, all Trial Supplies and Confidential Information furnished by Sponsor or its designees to Institution or Investigator. Upon completion of the Trial, the terms of Sections 15.3(a) through 15.3(e) will apply as of the Trial completion date. Within thirty (30) days of termination of this Agreement, Investigator will submit final written reports to Sponsor as specified in the Protocol. 15.3 Účinky výpovědi a dokončení klinického hodnocení. V případě předčasného ukončení (vypovězení) na základě článku 15.2: (a) skončí platnost této smlouvy; (b) zkoušející okamžitě přestane do klinického hodnocení nabírat nové subjekty hodnocení, přestane podávat studijní léčivo subjektům hodnocení a přestane provádět vyšetření subjektů hodnocení pro účely klinického hodnocení, pokud je to z lékařského hlediska možné; (c) zadavatel uhradí zdravotnickému zařízení přiměřené náklady, které mu vzniknou v souvislosti s prováděním klinického hodnocení do data jeho předčasného ukončení (výpovědi), v souladu s přílohou A, včetně neodvratných nákladů, které vznikly před datem výpovědi; (d) všechny částky, které na základě shora uvedených výpočtů ještě nebyly splatné, ale již byly vyplaceny, je poskytovatel povinno neprodleně zadavateli vrátit; a (e) poskytovatel se zavazuje (i) předat zadavateli do třiceti (30) dnů od data nabytí účinnosti výpovědi, všechna data z klinického hodnocení, včetně vyplněných či částečně vyplněných záznamů pacienta (CRFs); a (ii) na základě pokynů zadavatele (a výlučně na základě volby zadavatele): buď zada...
View Source

Related to Effects of Termination or Trial Completion

  • Effects of Termination In the event of any termination of this Agreement as provided in Section 5.1, this Agreement (other than Section 3.2(b), this Section 5.2 and ARTICLE VI (other than Sections 6.1 and 6.2) and all applicable defined terms, which shall remain in full force and effect) shall forthwith become wholly void and of no further force and effect; provided that nothing herein shall relieve any party from liability for willful breach of this Agreement.

  • Events of Termination Subject to Section 6.4 below, this Agreement will terminate as to a Fund: (a) at the option of any party, with or without cause with respect to the Fund, upon six (6) months advance written notice to the other parties, or, if later, upon receipt of any required exemptive relief from the SEC, unless otherwise agreed to in writing by the parties; or (b) at the option of AVIF upon institution of formal proceedings against LIFE COMPANY or its affiliates by the NASD, the SEC, any state insurance regulator or any other regulatory body regarding LIFE COMPANY's obligations under this Agreement or related to the sale of the Contracts, the operation of each Account, or the purchase of Shares, if, in each case, AVIF reasonably determines that such proceedings, or the facts on which such proceedings would be based, have a material likelihood of imposing material adverse consequences on the Fund with respect to which the Agreement is to be terminated; or (c) at the option of LIFE COMPANY upon institution of formal proceedings against AVIF, its principal underwriter, or its investment adviser by the NASD, the SEC, or any state insurance regulator or any other regulatory body regarding AVIF's obligations under this Agreement or related to the operation or management of AVIF or the purchase of AVIF Shares, if, in each case, LIFE COMPANY reasonably determines that such proceedings, or the facts on which such proceedings would be based, have a material likelihood of imposing material adverse consequences on LIFE COMPANY, or the Subaccount corresponding to the Fund with respect to which the Agreement is to be terminated; or (d) at the option of any Party in the event that (i) the Fund's Shares are not registered and, in all material respects, issued and sold in accordance with any applicable federal or state law, or (ii) such law precludes the use of such Shares as an underlying investment medium of the Contracts issued or to be issued by LIFE COMPANY; or (e) upon termination of the corresponding Subaccount's investment in the Fund pursuant to Section 5 hereof; or (f) at the option of LIFE COMPANY if the Fund ceases to qualify as a RIC under Subchapter M of the Code or under successor or similar provisions, or if LIFE COMPANY reasonably believes that the Fund may fail to so qualify; or (g) at the option of LIFE COMPANY if the Fund fails to comply with Section 817(h) of the Code or with successor or similar provisions, or if LIFE COMPANY reasonably believes that the Fund may fail to so comply; or (h) at the option of AVIF if the Contracts issued by LIFE COMPANY cease to qualify as annuity contracts or life insurance contracts under the Code (other than by reason of the Fund's noncompliance with Section 817(h) or Subchapter M of the Code) or if interests in an Account under the Contracts are not registered, where required, and, in all material respects, are not issued or sold in accordance with any applicable federal or state law; or (i) upon another Party's material breach of any provision of this Agreement.

  • Consequences of Termination on Notice by the Province If the Province terminates the Agreement pursuant to section A11.1, the Province may take one or more of the following actions: (a) cancel further instalments of Funds; (b) demand from the Recipient the payment of any Funds remaining in the possession or under the control of the Recipient; and (c) determine the reasonable costs for the Recipient to wind down the Project, and do either or both of the following: (i) permit the Recipient to offset such costs against the amount the Recipient owes pursuant to section A11.2(b); and (ii) subject to section A4.1(a), provide Funds to the Recipient to cover such costs.

  • Certain Effects of Termination If this Agreement is terminated as provided in Section 6.01, except as set forth in Section 7.03, this Agreement shall become null and void and have no further force or effect, but the parties shall not be released from any liability arising from or in connection with any breach hereof occurring prior to such termination.

  • Contents of Termination Notice A Termination Notice shall specify: (a) the nature of the relevant Event of Default; (b) a date and time, which shall be reasonable in the circumstances, at which termination is to take effect; and (c) whether the party serving the Termination Notice reasonably considers that the Event of Default is capable of remedy, and where the relevant Event of Default is capable of remedy: (i) the steps which the party serving the Termination Notice believes are reasonably required to remedy the Event of Default; and (ii) a reasonable grace period within which such steps may be taken (where the Event of Default is a failure of the Train Operator to pay Track Charges or other amounts due, seven days is a reasonable grace period).